|
1
|
Williams R: Global challenges in liver
disease. Hepatology. 44:521–526. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shepard CW, Finelli L and Alter MJ: Global
epidemiology of hepatitis C virus infection. Lancet Infect Dis.
5:558–567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Deuffic-Burban S, Poynard T, Sulkowski MS
and Wong JB: Estimating the future health burden of chronic
hepatitis C and human immunodeficiency virus infections in the
United States. J Viral Hepat. 14:107–115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ly KN, Hughes EM, Jiles RB and Holmberg
SD: Rising mortality associated with hepatitis C virus in the
united states, 2003–2013. Clin Infect Dis. 62:1287–1288. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chung RT: Acute hepatitis C virus
infection. Clin Infect Dis. 41 Suppl 1:S14–S17. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ghany MG, Strader DB, Thomas DL and Seeff
LB: American Association for the Study of Liver Diseases.
Diagnosis, management and treatment of hepatitis C An update.
Hepatology. 49:1335–1374. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Manns MP, McHutchison JG, Gordon SC,
Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M
and Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with
interferon alfa-2b plus ribavirin for initial treatment of chronic
hepatitis C: A randomised trial. Lancet. 358:958–965. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fried MW, Shiffman ML, Reddy KR, Smith C,
Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G,
Dhumeaux D, et al: Peginterferon alfa-2a plus ribavirin for chronic
hepatitis C virus infection. N Engl J Med. 347:975–982. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Poynard T, Marcellin P, Lee SS, Niederau
C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C and
Albrecht J: Randomized trial of interferon alpha2b plus ribavirin
for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo
for 48 weeks for treatment of chronic infection with hepatitis C
virus. International Hepatitis Interventional Therapy Group (IHIT).
Lancet. 352:1426–1432. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Okanoue T, Itoh Y, Minami M, Sakamoto S,
Yasui K, Sakamoto M, Nishioji K, Murakami Y and Kashima K:
Interferon therapy lowers the rate of progression to hepatocellular
carcinoma in chronic hepatitis C but not significantly in advanced
stage: A retrospective study in 1148 patients. Viral Hepatitis
Therapy Study Group. J Hepatol. 30:653–659. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Booth JC, O'Grady J and Neukerger J: Thr
Royal College of Physicians of London and the British Society of
Gastroenterology: Clinical guidelines on the management of
hepatitis C. Gut. 49 Suppl 1:I1–I21. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ray SC, Arthur RR, Carella A, Bukh J and
Thomas DL: Genetic epidemiology of hepatitis C virus throughout
Egypt. J Infect Dis. 182:698–707. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shiha G and Salem S: Interferon alone or
in combination with ribavirin for the treatment of chronic
hepatitis C genotype IV. J Hepatol. 36:1292002. View Article : Google Scholar
|
|
14
|
El Makhzangy H, Esmat G, Said M, Elraziky
ME, Shouman S, Refai R, Rekacewicz C, Gad RR, Vignier N,
Abdel-Hamid M, et al: Response to pegylated interferon alfa-2a and
ribavirin in chronic hepatitis C genotype 4. J Med Virol.
81:1576–1583. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Esmat G and Fattah S Abdel: Evaluation of
a novel pegylated interferon alpha-2a (Reiferon Retard®)
in Egyptian patients with chronic hepatitis C-genotype 4. Digest
Liver Dis. 3:17–19. 2009.
|
|
16
|
Yagil R and van Creveld C: Medicinal use
of camel milk. Fact or Fancy?Proceedings of the 2nd International
Camelid Conference on Agro-economics of Camelids. Almaty;
Kazahstan: 2000
|
|
17
|
Yagil R and Combs SB: The Desert Camel:
Comparative Physiological AdaptationComparative Animal Nutrition.
5. Karger, Basel: 1985
|
|
18
|
Hanna J Over the hump. Jack Hanna's Animal
Adventures. TV series (USA) 2001 season. #2190. http://www.animaladventures.com
|
|
19
|
Merin U, Bernstein SD, Bloch-Damti N,
Yagil R, van Creveld C and Lindner P: A comparative study of milk
proteins in camel (Camelus dromedarius) and bovine colostrum.
Livestock Product Sci. 67:297–301. 2001. View Article : Google Scholar
|
|
20
|
Beg OU, von-Bahr-Lindstström H, Zaidi ZH
and Jörnvall H: Characterisation of camel milk protein rich proline
identifies a new beta casein fragment. Regul Pept. 15:55–61. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Evans EW: Uses of milk proteins in
formulated foodsDevelopments in Food Proteins. Hudson BJF: Applied
Science; London: 1982
|
|
22
|
EL-Fakharany EM, Serour EA, Abdelrahman
AM, Haroun BM and Redwan el-RM: Purification and characterization
of camel (Camelus dromedarius) milk amylase. Prep Biochem
Biotechnol. 39:105–123. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hamers-Casterman C, Atarhouch T,
Muyldermans S, Robinson G, Hamers C, Songa E Bajyana, Bendahman N
and Hamers R: Naturally occurring antibodies devoid of light
chains. Nature. 363:446–448. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Håkansson A, Zhivotovsky B, Orrenius S,
Sabharwal H and Svanborg C: Apoptosis induced by a human milk
protein. Proc Natl Acad Sci. 92:8064–8068. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Harmsen MC, Swart PJ, de Bethune MP,
Pauwels R, De Clercq E, The TH and Meijer DK: Antiviral effects of
plasma and milk proteins: Lactoferrin shows potent activity against
both human immunodeficiency virus and human cytomegalovirus
replication in vitro. J Infect Dis. 172:380–388. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Redwan el-RM and Tabll A: Camel
lactoferrin markedly inhibits hepatitis C virus genotype 4
infection of human peripheral blood leukocytes. J Immunoassay
Immunochem. 28:267–277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
El-Fakharany EM, Tabll A, El-Wahab AA,
Haroun BM and Redwan EM: Potential activity of camel milk-amylase
and lactoferrin against hepatitis C virus infectivity in HepG2 and
lymphocytes. Hepatitis Monthly. 8:101–109. 2008.
|
|
28
|
Valenti P and Antonini G: Lactoferrin: An
important host defense against microbial and viral attack. Cell Mol
Life Sci. 62:2576–2587. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
El-Fakharany EM, Haroun BM, Ng TB and
Redwan EM: Oyster mushroom laccase inhibits hepatitis C virus entry
into peripheral blood cells and hepatoma cells. Protein Pept Lett.
17:1031–1039. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rao MB, Gupta RC and Dastur NN: Camels'
milk and milk products. Ind J Dairy Sci. 23:71–78. 1970.
|
|
31
|
Kaskous S: Importance of camel milk for
human health. Emir J Food Agric. 28:158–163. 2016.
|
|
32
|
Almahdy O, EL-Fakharany EM, EL-Dabaa E, Ng
TB and Redwan EM: Examination of the activity of camel milk casein
against hepatitis C virus (genotype-4a) and its apoptotic potential
in hepatoma and hela cell lines. Hepat Mon. 11:724–730. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liao Y, El-Fakharany E, Lönnerdal B and
Redwan EM: Inhibitory effects of native and recombinant full-length
camel lactoferrin and its N and C lobes on hepatitis C virus
infection of Huh7.5 cells. J Med Microbiol. 61:375–383. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
EL-Fakharany EM, Abedelbaky N, Haroun BM,
Sánchez L, Redwan NA and Redwan EM: Anti-infectivity of camel
polyclonal antibodies against hepatitis C virus in Huh7.5 hepatoma.
Virol J. 9:2012012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
EL-Fakharany EM, Haroun BM, Redwan NA,
Sánchez L and Redwan EM: Potential activity of camel milk proteins
on the cellular infectivity of hepatitis C virus. Virol J.
9:2012012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
El-Fakharany EM, Sánchez L, Al-Mehdar HA
and Redwan EM: Effectiveness of human, camel, bovine and sheep
lactoferrin on the hepatitis C virus cellular infectivity:
Comparison study. Virol J. 10:1992013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Redwan EM, Uversky VN, El-Fakharany EM and
Al-Mehdar H: Potential lactoferrin activity against pathogenic
viruses. C R Biol. 337:581–595. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Albar AH, Almehdar HA, Uversky VN and
Redwan EM: Structural heterogeneity and multifunctionality of
lactoferrin. Curr Protein Pept Sci. 15:778–797. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Redwan EM, El-Fakharany EM, Uversky VN and
Linjawi MH: Screening the anti infectivity potentials of native N-
and C-lobes derived from the camel lactoferrin against hepatitis C
virus. BMC Complement Altern Med. 14:2192014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Almehdar HA, El-Fakharany EM, Uversky VN
and Redwan EM: Disorder in milk proteins: Structure, functional
disorder, and biocidal potentials of lactoperoxidase. Curr Protein
Pept Sci. 16:352–365. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Redwan EM, Almehdar HA, EL-Fakharany EM,
Baig AWK and Uversky VN: Potential antiviral activities of camel,
bovine, and human lactoperoxidases against hepatitis C virus
genotype 4. RSC Adv. 5:60441–60452. 2015. View Article : Google Scholar
|
|
42
|
Redwan EM, El-Baky NA, Al-Hejin AM,
Baeshen MN, Almehdar HA, Elsaway A, Gomaa AB, Al-Masaudi SB,
Al-Fassi FA, Abu Zeid IE and Uversky VN: Significant antibacterial
activity and synergistic effects of camel lactoferrin with
antibiotics against methicillin-resistant Staphylococcus aureus
(MRSA). Res Microbiol. 167:480–491. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dogar MZ Hassan, Nazir T, Akram H,
Nasir-ud-Din A and Farooq M: Molecular study of human HCV RNA by
real time-polymerase chain reaction, viral kit and RoboGene
quantification. Cell Mol Biol. 61:22015.PubMed/NCBI
|
|
44
|
Redwan el-RM, Fahmy A, El Hanafy A, Abd
EL-Baky N and Sallam SM: Ovine anti-rabies antibody production and
evaluation. Comp Immunol Microbiol Infect Dis. 32:9–19. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
EL-Baky NA, Omar SH, EL-Badry H and Redwan
el-RM: Efficacy comparison of gel-based, membrane and glass array
techniques to detect human antibodies isotypes among the Egyptian
HCV-patients. Hum Antibodies. 17:63–71. 2008.PubMed/NCBI
|
|
46
|
Thompson JD, Higgins DG and Gibson TJ:
CLUSTAL W Improving the sensitivity of progressive multiple
sequence alignment through sequence weighting, position specific
gap penalties and weight matrix choice. Nucleic Acids Res.
22:4673–4680. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kuiken C, Yusim K, Boykin L and Richardson
R: The Los Alamos hepatitis C sequence database. Bioinformatics.
21:379–384. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fields GB and Noble RL: Solid phase
peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids.
Int J Pept Protein Res. 35:161–214. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Boysen RI and Hearn MT: Purification of
peptides from solid-phase peptide synthesis with RP-HPLC. CSH
Protoc. 2006:pdb.prot45482006.PubMed/NCBI
|
|
50
|
Conover WJ: Practical nonparametric
statistic. 2nd edition. John Wiley and Sons; New York: 1971
|
|
51
|
el-Zayadi A, Simmonds P, Dabbous H,
Prescott L, Selim O and Ahdy A: Response to interferon-alpha of
Egyptian patients infected with hepatitis C virus genotype 4. J
Viral Hepat. 3:261–264. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kamal SM, El Tawil AA, Nakano T, He Q,
Rasenack J, Hakam SA, Saleh WA, Ismail A, Aziz AA and Madwar MA:
Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis
C genotype 4: Impact of treatment duration and viral kinetics on
sustained virological response. Gut. 54:858–866. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
El-Zanaty F and Way A: Egypt Demographic
and Health Survey 2008. Egyptian Ministry of Health. El-Zanaty and
Associates and Macro International. 4312009.
|
|
54
|
Zekri AK, Ashour MS, Hassan A, El-Din H
Alam, El-Shehaby AM and Abu-Shady MA: Cytokine profile in Egyptian
hepatitis C virus genotype-4 in relation to liver disease
progression. World J Gastroenterol. 11:6624–6630. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
El-Baky NA, Omar SH and Redwan EM: The
anti-cancer activity of human consensus interferon-alpha
synthesized in cell-free system. Protein Expr Purif. 80:61–67.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Mohammed Y, El-Baky NA and Redwan EM:
Expression, purification, and characterization of recombinant human
consensus interferon-alpha in Escherichia coli under λp(L)
promoter. Prep Biochem Biotechnol. 42:426–447. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Elattar G, Saleh Z, EL-Shebini S, Farrag
A, Zoheiry M, Hassanein A, EL-Ghannam M, Shendy S, EL-Dabaa E and
Zahran N: The use of whey protein concentrate in management of
chronic hepatitis C virus-a pilot study. Arch Med Sci. 5:748–755.
2010. View Article : Google Scholar
|
|
58
|
Abbas S, Imran R, Nazir A, Qamar MF and
Sarfraz L: Effect of camel milk supplementation on blood parameters
and liver function of hepatitis patients. Am J Ethnomedicine.
1:129–146. 2014.
|
|
59
|
Mohamed WA, Schaalan MF and El-Abhar HS:
Camel milk: Potential utility as an adjunctive therapy to
Peg-IFN/RBV in HCV-4 infected patients in Egypt. Nutr Cancer.
67:1305–1313. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Park GJH, Lin BP, Ngu MC, Jones DB and
Katelaris PH: Aspartate aminotransferases: Alanine
aminotransferases ratio in chronic hepatitis C infection: Is it a
predictor of cirrhosis? J Gastroenterol Hepatol. 15:386–390. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Rosalki SB and Mcintyre N: Biochemical
investigations in the management of liver diseaseOxford textbook of
clinical hepatology. 2nd edition. New York: Oxford university
press; pp. 503–521. 1999
|
|
62
|
Thapa BR and Walia A: Liver function tests
and their interpretation. Indian J Pediatr. 74:663–671. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Roitt V, Brostoff J and Male D:
Immunology. 6th edition. Goldsby, Kindt, Osborne, Kuby. Freeman
& Company; pp. 8.4–8.5. 2006
|
|
64
|
Saltanat H, Li H, Xu Y, Wang J, Liu F and
Geng XH: The influences of camel milk on the immune response of
chronic hepatitis B patients. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi.
25:431–433. 2009.(In Chinese). PubMed/NCBI
|
|
65
|
Gigi E, Raptopoulou-Gigi M, Kalogeridis A,
Masiou S, Orphanou E, Vrettou E, Lalla TH, Sinakos E and Tsapas V:
Cytokine mRNA expression in hepatitis C virus infection: TH-1
predominance in patients with chronic hepatitis C and TH1-TH2
cytokine profile in subjects with self-limited disease. J Viral
Hepat. 15:145–154. 2008.PubMed/NCBI
|
|
66
|
Breitling L: Insulin and anti-diabetes
activity of camel milk. J Camel Practice Research. 9:43–45.
2002.
|
|
67
|
Martin F, Volpari C, Steinkuhler C, Dimas
N, Brunetti M, Biasiol G, Altamura S, Cortese R, De Francesco R and
Sollazzo M: Affinity selection of a camelized V(H) domain antibody
inhibitor of hepatitis C virus NS3 protease. Protein Eng.
10:607–614. 1997. View Article : Google Scholar : PubMed/NCBI
|
